Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

By Ogura Michinori   Hatake Kiyohiko   Tobinai Kensei   Uchida Toshiki   Suzuki Tatsuya   Terui Yasuhito   Yokoyama Masahiro   Maruyama Dai   Mori Masakazu   Jewell Roxanne C.   Katsura Koichi   Hotta Tomomitsu  

Japanese Journal of Clinical Oncology, Vol. 43, Iss. 5, 2013-05 ,pp. : 466-475

Oxford University Press

Access to resources Recommend Favorite

Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-CELL chronic lymphocytic leukemia

By Cavalli-Björkman Nina   Ösby Eva   Lundin Jeanette   Kalin Mats   Österborg Anders   Gruber Astrid  

Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. : 277-280

Humana Press, Inc

Access to resources Recommend Favorite

Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine

By                  

International Journal of Oncology, Vol. 43, Iss. 2, 2013-01 ,pp. : 670-676

Spandidos Publications

Access to resources Recommend Favorite

Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma

By Antonini Giovanni   Cox Maria   Montefusco Enrico   Ferrari Antonella   Conte Esmeralda   Morino Stefania   Latino Pamela   Trasimeni Guido   Monarca Bruno  

Journal of Neuro-Oncology, Vol. 81, Iss. 2, 2007-01 ,pp. : 197-199

Springer Publishing Company

Access to resources Recommend Favorite

Functional inactivation of CD4+CD25 high regulatory T cells using low dose human/mouse chimeric anti-CD25 monoclonal antibody enhanced lymphokine-activated killer cells activity

By Okita Riki  

Targeted Oncology, Vol. 3, Iss. 4, 2008-10 ,pp. : 227-234

Springer Publishing Company

Access to resources Recommend Favorite